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An account of data entry inconsistencies and
their impact on positron emission tomography
quantiﬁcation
Tram Nguyen, PhDa,b, Christina Baun, Bsca,c, Poul Flemming Høilund-Carlsen, MD, DMSca,c,
∗
Abstract
Reproducibility is essential to clinical application of positron emission tomography (PET) quantiﬁcation. Human lapses in data
registration and protocol compliance are pervasive sources of intrasite quantiﬁcation variability. Although rarely assessed or reported,
these lapses are ultimately a limitation to harmonization in multicenter clinical trials. A comprehensive account of their possible extent
is relayed here.
This is a retrospective audit of errors in manual registration of study parameters and in protocol adherence across a sample of in-
center research projects over one year (201 patients, 222 PET/CT scans). Discrepancies in patient height and weight; tracer type;
dose; injection; and scan times were listed. Correspondent variances in standardized uptake values (SUVs) normalized by body
weight, SUV (BW), and body surface area, SUV (BSA), were assessed.
Manual misregistrations totalled 41.8%. These were mainly small, but with a few large deviations, and most signiﬁcant in weight
(range: -1–100kg) and dose (-19 to 12 MBq). Errors were more frequent and generally larger in non-routine studies. This also applied
to protocol compliance. A 50.7% noncompliance was found with signiﬁcant deviations in dose (-106 to 208 MBq) and especially in
early scan uptake times (-37 to 54min). Although misregistrations did not overall translate into signiﬁcant SUV variability,
noncompliance did. These errors contributed a factor 0.02 to 1.45 and 0.71 to 3.09 SUV (BW) change, respectively. SUV (BSA) saw a
signiﬁcant 21% to 22% decrease with mistyped height and weight.
Inconsistency was frequent but less prominent in data entry than in protocol compliance. As both caused some substantial SUV
variances, intra-site assessments and data checking are required for clinical trials.
Abbreviations: BSA = body surface area, BW = body weight, DICOM = digital imaging and communications in medicine, FDG =
2-deoxy-2-ﬂuoro-D-glucose, NaF = sodium ﬂuoride, PET/CT = positron emission tomography/computed tomography, SUV =
standardized uptake value.
Keywords: compliance, error sources, positron emission tomography, protocol, quantitative evaluation, reproducibility of results
1. Introduction
Quantitative disease indices are widely used in positron emission
tomography/computed tomography (PET/CT) studies. The preva-
lent standardized uptake value (SUV), which is known to be
afﬂicted by biases,[1–6] requires assessment of error levels for
reliable clinical applications, for example, diagnosis and response
monitoring. Although much has been done to estimate various
physiological,[7–9] physical,[10–14] and technical [15–18] variabilities,
the bias magnitude of human error is hardly reported. Speciﬁcally,
entry errors in data registers and within-center compliance
variance are often ignored yet ubiquitous sources of unreliable
SUVs. These errors reduce reproducibility and thus also compro-
mise multi-center standardization.
Lapses in practice seem inevitable, given the numerous steps
and diverse protocol procedures, ranging from routine 2-deoxy-
2-[18F]-ﬂuoro-D-glucose ([18F]-FDG) examinations to lesser
common tracer studies, such as [18F]-sodium ﬂuoride ([18F]-
NaF) PET/CT. Frequent error occurrence has also been
acknowledged in the literature[5] as an important aspect to
consider.[19] Although impactful error in single data entries[20]
and compliance across centers[21–26] has been observed, the
quantitative extent and impact of everyday practical data
miregistrations and variability have not been reported, to the
best of our knowledge. Such a collective assessment is provided
here for a typical clinical routine setting.
2. Methods
A systematic review of work practices was carried out in our
department as a clinical site counting 5 PET/CT scanners, 47
trained technologists, and 7298 PET/CT scans conducted for the
year of 2016 with a general yearly throughput of 1000 patients.
The retrospective assessment covered PET/CT studies performed
at our institution from January 2015 to January 2016 as a
representative cross-section. These included 5 different research
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projects comprising a total of 201 patient studies (222 scans) and
both [18F]-FDG-PET/CT of various protocols (single and dual
time point scans) and [18F]-NaF-PET/CT for comparison. The
projects and protocol details are listed in Table 1. No ethical
approval was required for this type of study.
Although the department has no EU accreditation, all
procedures followed the institutional standards mainly based
on the European Association of Nuclear Medicine guidelines.[27]
As per routine, basic patient information was registered in
individual handwritten record forms during patient preparation
before tracer injection with the Intego system (MEDRAD, Inc.).
Output prints of administered dose readings were included in the
patient records. The same data were then typed for DICOM
metadata entries at the scanner console before each scan, wherein
acquisition commencement times were further noted in the
patient record. Data and image quality were not checked by a
core laboratory, whereas double reading was employed in
diagnostic reporting.
2.1. Data extraction
For the patient studies included in this work, data registrations in
the handwritten records were collected regarding basic patient
data (weight, height, measured blood sugar level) as well as scan-
related parameters: tracer type and dose, injection time (Tinj), and
scan time (T). The corresponding typedDICOMmetadata entries
were looked up in the image ﬁles for comparison. Additional
recording of variations from protocol prescriptions (Table 1) was
carried out where applicable. In subsequent accounts of data
entry inconsistencies, any whole number deviations were listed.
Those relative to the protocol were further reworked, taking into
consideration our institution’s guideline-based [28] standard
practical allowances of ±10% in dose and ±5minutes in tracer
uptake time (DT).
2.2. Quantitation analysis
The impact of differing data entries used in quantitative analyses
was evaluated in relation to common SUV calculations. SUVs
were given as the tissue activity concentration, C(T) [kBq/mL],
normalized by a factor, V, which accounts for distribution
volume, V, and injected dose, Dinj [MBq], corrected by a decay
factor f ¼ el⋅t with decay constant l:
SUV ¼ CðTÞ⋅V ¼ CðTÞ⋅ V
Dinj⋅f
ð1Þ
where for the FDG distribution volume, patient body
weight (BW) is mostly used, V=BW [kg], or alternatively,
the body surface area (BSA), calculated as V=BSA1 [m
2]=
BW [kg]0.425 · H [cm]0.725 ·0.007184 or V=
BSA2½m2 ¼ 100
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
BW½kg⋅H½cm=3600p ,[29] which includes
patient height, H. From Eq. (1), variance estimates in
calculated SUVs between deviating parameter entries (a, b)
were found in terms of ratios:
SUVa
SUVb
¼ CðTaÞ⋅Va
CðTbÞ⋅Vb
¼ Ca
Cb
⋅
Va
Vb
⋅
Dinj;b
Dinj;a
⋅
el⋅DTb
el⋅DTa
¼ UC⋅RV ⋅RDose⋅RDT
ð2Þ
which for a given time point scan (uptake ratioUC=1) amount to
separate contributing factors of parameter ratios between
discrepant entries of distribution volume, RV, dose, RDose, and
uptake time,RDT, respectively. In variations from protocol target
levels, expected deviant concentrations (UC ≠ 1) would further
impact SUV variance.
Differences in corresponding data registrations were graphi-
cally assessed by Bland-Altman plots. As neither raw nor log-
transformed data were generally normally distributed, statistical
tests for the null hypothesis were performed where relevant with
2-sided Wilcoxon signed-rank matched-pairs tests of entry
differences and log ratios of SUV factors. Here, statistical
signiﬁcance was inferred at P value <.05. All data analyses were
carried out in MATLAB 9.0 (MathWorks, Inc.).
3. Results
Three delayed time scans in dual point FDG were not performed
for unspeciﬁed reasons and were disregarded in the listings. No
missing data were otherwise found in the DICOM ﬁles, but some
scan time entries were omitted in patient records (12/222 ≈
5.4%). The error listings also excluded the often noncompulsory
blood sugar measurements. Total accounts showed errors to be
predominantly small, but with a few large discrepancies. In terms
of whole number deviation, 41.8% (79/189, excluding missing
entries) of the patient studies showed inconsistencies between
patient records and DICOM entries. Moreover, 98.0% (197/
201) differed from protocol targets, 50.7% (102/201) of which
were noncompliant with allowed variations (dose±10%, DT±
5min). Manual misregistrations occurred to a lesser extent in
routine FDG–60minutes (54/150 ≈ 36.0%) than in FDG–dual
time (11/20 ≈ 55.0%), NaF–45minutes (8/10 ≈ 80.0%) or NaF–
60minutes (6/9 ≈ 66.7%) protocol studies. Meanwhile, the
missing data entries only appeared in FDG studies.
Of individual entries, tracer dose and scan times were most
prone to registration disparity. This was largely seen indepen-
dently of study and tracer type (Figure 1). Differences tested
Table 1
Project type, population sizes and protocol prescriptions.
Project Tracer Sample size (n) Uptake time Dose (min–max)
A FDG 5 Dual (1–3 h) 4 MBq/kg (200–400 MBq)
B FDG 15 Dual (1–3 h) 4 MBq/kg (200–400 MBq)
NaF 10 45 min 200 MBq
C FDG 147 60 min 4 MBq/kg (200–400 MBq)
FDG 3 Dual (1–3 h) 4 MBq/kg (200–400 MBq)
D FDG 1 Dual (45–60 min) 4 MBq/kg (200–400 MBq)
E FDG 11 60 min 4 MBq/kg (200–400 MBq)
NaF 9 60 min 2 MBq/kg
FDG=2-deoxy-2-ﬂuoro-D-glucose, NaF= sodium ﬂuoride.
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statistically among all entries or between deviating entries alone
yielded the same results. They showed dose discrepancies to be
generally signiﬁcant, whereas uptake times were only so relative
to protocol prescriptions (P< .001). DICOM metadata only
differed signiﬁcantly from patient records in weight by (mean±
SD) 25.4±40.3kg (P ≈ .02) and in dose by 4.1±7.7 MBq (P ≈
.02). Differences for all recorded data entries versus their mean
are shown in Figure 2.
Discordances related to tracer type were not only more
frequent but also generally larger in NaF studies than in FDG
studies. Patient record and DICOM entry differences in FDG
studies averaged in height: 36.4±78.9cm (P ≈ .44); weight: 28.7
±42.3kg (P ≈ .03); dose: 3.3±7.7 MBq (P ≈ .10); Tinj: 1.0±
3.5minutes (P=1.0); early scan time T1: 1.1±8.9minutes (P ≈
.93); delayed scan time T2: 0.3±5.3minutes (P ≈ .78); and
related uptake times DT1: 1.3±9.1minutes (P ≈ .82); DT2:
0.7±5.2minutes (P=1.0). Corresponding entries in NaF
studies had single errors in height and weight and deviations
in dose: 6.5±8.4 MBq (P ≈ .13); Tinj: 4.7±4.6minutes
(P= .25); T1: 2.3±3.4minutes (P ≈ .03); and DT1: 0.0±5.8
minutes (P=1.0).
Departures from protocol prescriptions not only contributed
predominantly to disparity counts but were typically also most
signiﬁcant. Figure 3 details the totals and magnitudes of the
tallied inconsistencies. These were signiﬁcant for dose and DT1
(P< .001), but not DT2 (P ≈ .45). Again, overall smaller practical
Figure 1. Bar diagrams of percentage inconsistent data registrations (excl. missing entries) between patient records and DICOM metadata for all studies (A) and
individual study types (B) in entries of patient height and weight, tracer type and dose, tracer injection time (Tinj) as well as early (T1) and late (T2) scan times.
Figure 2. Bland-Altman plots of differences in all registered patient height (A), weight (B), tracer dose (C), injection time (D), scan times (E), and uptake times (F)
between data entries in the patient records, image DICOM metadata, and study protocol prescriptions, respectively. Solid and dashed lines indicate mean±2SD.
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variations were seen for FDG studies than for NaF studies with
deviations in dose: 5.6±17.9 MBq (P< .001); DT1: 6.1±9.1
minutes (P< .001); DT2: 2.1±9.2min (P ≈ .45); and dose:
7.6±58.5 MBq (P ≈ .22); DT1: 9.4±8.7minutes (P< .001),
respectively.
3.1. Quantitative impact
Variations in SUV normalization factors, V, calculated for
deviant data entries can be seen in Figure 4A and B. For BW-
based indices, SUV (BW), discrepant patient record and DICOM
entries did not overall translate into signiﬁcant SUV deviations (P
≈ .4). There, only error contributions RWeight and RDose signiﬁed
a signiﬁcant 0.72±0.43 (P ≈ .02) and 1.02±0.03 (P ≈ .02) times
change in SUV, respectively.
Inconsistencies with the prescribed protocol were found to be
generally signiﬁcant (P< .001). This only applied for early T1 but
not late T2 time scans when tested separately. Such differences in
DICOM (dic) and protocol (prot) entry SUV levels were by a
factor RAll=Vdic/Vprot of 1.10±0.25 (P< .001) for T1 and 1.03
±0.10 (P ≈ .12) for T2 scans. Similar differences were seen for
patient record entries (rec) by a factor RAll=Vrec/Vprot of 1.10±
0.25 (P< .001) and 1.01±0.06 (P ≈ .43). In the extraction of
compliance variation, clocked scan time DICOM entries were
considered more reliable than those in patient records and
inversely so for all other recordings yielding the V variances seen
in Figure 4C. Mistyped data in DICOM ﬁles did not appear to
confound actual compliance-related variance, as SUVdic variation
overall reﬂected ﬂuctuations in protocol adherence. Proportional
differences were, on the whole, otherwise similar to those of
separate FDG studies (Table 2).
For BSA-based measures, height and weight misregistrations
seen in about 6.5% (13/201) of all studies amounted to
concomitantly signiﬁcant BSA and SUV (BSA) deviations
(Figure 4D). These errors gave DICOM-based SUV(BSA1) levels
an average 0.79±0.37 times those with patient record entries (P
≈ .01) and a corresponding factor of 0.78±0.38 (P ≈ .003) in
SUV(BSA2). Although the deviations pertaining to FDG studies
remained signiﬁcant (BSA1: 0.75±0.40, P ≈ .02; BSA2: 0.74±
0.41, P ≈ .01), those in NaF studies generally did not (BSA1: 0.98
±0.03, P= .5; BSA2: 0.98±0.02, P= .5). Between all correspond-
ing DICOM and patient record entries, SUV (BSA) discordances
overall, as well as among deviating entries only, were not
signiﬁcant (P ≈ .8) in this sample.
4. Discussion
The present study conﬁrms that data registration errors are
somewhat common, as implied in the literature.[5,25] Further-
more, the high frequency of protocol nonconformity seen is also
in line with other studies.[25,26,30,31] However, we found manual
misregistrations to be predominantly minor, with few signiﬁcant
discrepancies. Although no similar studies have been found to
verify the generality of this ﬁnding, there is support in the
literature. For instance, 0.8% to 7.4% of weight entries in patient
reports deviated from actual values by >±10% in one study.[20]
Figure 3. Number of entries noncompliant with protocol prescriptions shown as bar charts for patient record (A) and DICOM metadata (B) registrations, with and
without deviations within allowed limits. Corresponding boxplots (C, D) of discrepancies, including (gray) and excluding (white) allowed deviations, display the range
of variation in tracer dose [MBq] and uptake times [minutes] at early (DT1) and late (DT2) scans.
Nguyen et al. Medicine (2018) 97:37 Medicine
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In the present study, this level of error was seen in 1.0% of the
deviations between DICOM entries and measured weights noted
in patient records. In contrast, mistyped dose in DICOM entries
appears widely undocumented. The 8.0% occurrence we
observed (all errors were <10%) was also low relative to
reported weight error rates. Although manual scan time
misrecordings, having the highest observed rate, also lack
reporting, one study did note misregistered times between
transmittal forms and DICOM data from 11 sites, giving
31.4%discrepant uptake times (>1min, max. difference 1hour 4
minutes).[25] In our listings, the analogous error count would
total 10.5% (max. difference 59minutes).
Our single-center error recordings thus appear generally lower
than reported levels. Still, comparison with reports is limited and
primarily involves intersite rather than intrasite accounts. Protocol
adherence evaluation is likewise primarily reported in cross-center
longitudinal variability [22,25,26] and test-retest repeatability [21,30]
studies. These have typically small per-site sample sizes (n ≲ 20).
No direct account is thus given of in-center compliance variation
across any study population, as is provided here.
Figure 4. Variation in normalization factors, V, for SUV (BW) calculations with deviating parameters in FDG (A) and NaF (B) studies as well as (C) between entries
most representative of true levels in acquired scans (Vacq) vs. protocol targets (Vproc), indicating parameter compliance variance. Similar plots for SUV (BSA)
between discrepant patient record (Vrec) and DICOM (Vdic) entries of height and/or weight (D). BSA=body surface area, FDG=2-deoxy-2-ﬂuoro-D-glucose, NaF=
sodium ﬂuoride, SUV=standardized uptake value.
Table 2
SUV (BW) parameter error ratios, R, between listed entries individually and collectively.
Study type Ratio RWeight RDose RDT1 RDT2 RAll
FDG SUVdic
SUVrec
0.68±0.45
∗
(0.02–1.01) 1.01±0.03 (0.95–1.07) 1.01±0.07 (0.95–1.45) 1.00±0.03 (0.96–1.07) 0.98±0.18 (0.02–1.45)
SUVrec
SUVprot
— 1.02±0.05† (0.88–1.32) 1.04±0.06† (0.71–1.26) 1.01±0.04 (0.95–1.11) 1.05±0.08† (0.71–1.36)
SUVdic
SUVprot
— 1.02±0.06† (0.88–1.41) 1.04±0.05† (0.71–1.26) 1.02±0.08 (0.92–1.30) 1.05±0.08† (0.71–1.46)
NaF SUVdic
SUVrec
0.99±0.00 (–) 1.03±0.04 (1.01–1.09) 1.00±0.04 (0.94–1.05) — 1.01±0.02 (0.99–1.05)
SUVrec
SUVprot
— 1.03±0.28 (0.52–1.95) 1.06±0.06† (0.98–1.17) — 1.55±0.60† (0.92–3.09)
SUVdic
SUVprot
— 1.03±0.27 (0.52–1.95) 1.06±0.06† (0.98–1.17) — 1.56±0.59† (0.92–3.09)
BW=body weight, FDG=2-deoxy-2-ﬂuoro-D-glucose, NaF= sodium ﬂuoride, SUV= standardized uptake value. Numbers are mean±SD (range) for SUV ratios between patient record registrations (SUVrec),
DICOM entries (SUVdic), and protocol prescriptions (SUVprot). Statistical signiﬁcance.∗
P< .05.
† P< .003.
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Our ﬁnding from our audit of practical procedures over a year
that non-compliance was the most generally signiﬁcant of errors
is in line with reports of low protocol adherence[25] and high
practical variability.[30] Especially uptake time variation is
acknowledged as an enduring problem in oncological PET,[32]
with considerable deviations noted in one single-center study.[30]
Yet, our account of a 52.7% and 71.4% compliance (within DT
±5minutes) for early and late scans, respectively, was compara-
tively better than reported multisite compliances of 31.4%[25]
and 35.0% [26] (both for DT±5minutes). Higher-dose compli-
ance of 93.0% (within dose±10%) was also seen, compared to a
reported 79% to 86% for FDG dose ±25% and [18F]-
deoxythymidine (FLT) dose ±10%.[22]
The above might suggest a perhaps expected higher variability
in multicenter than in single-center settings. It also would imply
highly variable intracenter error rates, which in some sites can be
greater than what we found. The generally seen higher
compliance in dose rather than uptake times is likely because
of a reduction in error resulting from widely replacing manual
with automated tracer administration.[33] However, retrospective
compliance evaluation like this relies on correct parameter
recordings without validation against true values. A prospective
study would better assess this.
As SUV calculation with commercial analysis software
generally uses parameters extracted from DICOM metadata,
we evaluated variation in DICOM based SUVdic against patient
record-based SUVrec as a ground truth proxy. Although entry
errors caused largely insigniﬁcant SUV variability, instances of a
98% to 45% factor different SUVdic can be consequential in
clinical applications. Variability naturally becomes more broadly
signiﬁcant in measures additionally reliant on height entries, as
seen in SUV (BSA) as an example. Moreover, the translation of
noncompliant dose and DT1 into overall signiﬁcant SUV error
factors can compromise comparability. The generally greatest
DT1 error contribution is also reported by others.
[21]
Thus frequent data entry inconsistencies can indeed cause
sizeable errors in quantitative analyses. This warrants parame-
ter checks as part of data processing. Overlooked errors can
affect patient management and SUV variability weakens the
power of clinical trials.[34] Data loss from lacking parameter
registration further reduces statistical power. Whereas missing
DICOM entries were not among our ﬁndings, a 5.4% to 32%
loss has been reported.[20,26,31] Also, noncompliance has caused
high data decimation in multicenter settings.[21,25,26] Our
observations substantiate a general signiﬁcance of such
parameter inconsistency. Hence, protocol standardization
alone does not sufﬁce for reliable translational trials. Intra-
center quantiﬁcation variability by human error in data
registration and compliance is an underlying limiting factor
to intercenter harmonization. It must be integrally assessed for
any such case. A greater transparency regarding reports of such
variances is equally called for.
This ﬁrst evaluation hence revealed a potentially signiﬁcant
clinical impact of data entry inconsistency and particularly non-
conform practices. Moving forward, ongoing work-ﬂow opti-
mization beyond staff training is therefore needed. Besides
persistent emphasis on correct data registration generally, data
checks, for example, peer-based, should be worked into practices.
Greater awareness of protocol adherence is imperative. Special
reminders and attention are required for less common protocols,
as errors were often linked to nonroutine practices, independent
of the time of day, wherein especially changedDT targets (NaF vs.
FDG studies) increased SUV variability. Prospective quality
control[21] and developments to automate procedures can also
promote reproducibility in clinical studies.
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